Shares of Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) traded down 10.1% during trading on Monday. The stock traded as low as $30.00 and last traded at $29.5510. 32,138 shares traded hands during trading, a decline of 70% from the average daily volume of 108,111 shares. The stock had previously closed at $32.88.
Analyst Ratings Changes
Several equities research analysts have weighed in on the stock. Stifel Nicolaus raised their target price on shares of Spyglass Pharma from $42.00 to $44.00 and gave the company a "buy" rating in a research note on Friday. Wall Street Zen raised Spyglass Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, October 31st. Raymond James Financial began coverage on Spyglass Pharma in a research note on Friday, August 14th. They set an "outperform" rating and a $39.00 target price on the stock. Weiss Ratings raised Spyglass Pharma from a "sell (e)" rating to a "sell (d-)" rating in a research report on Friday. Finally, UBS Group reiterated a "buy" rating on shares of Spyglass Pharma in a research note on Monday, October 5th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $45.83.
Get Our Latest Stock Report on SGP
Spyglass Pharma Stock Down 8.2%
The stock has a market capitalization of $1.01 billion and a PE ratio of -3.94. The firm has a 50 day moving average price of $28.78 and a 200-day moving average price of $24.83.
Spyglass Pharma (NASDAQ:SGP - Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.07). Equities analysts expect that Spyglass Pharma, Inc. will post -2.77 earnings per share for the current fiscal year.
Institutional Trading of Spyglass Pharma
Large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company purchased a new stake in shares of Spyglass Pharma in the first quarter valued at about $308,000. Bank of New York Mellon Corp purchased a new position in shares of Spyglass Pharma in the second quarter valued at $533,000. Bank of America Corp DE acquired a new stake in shares of Spyglass Pharma in the first quarter valued at approximately $726,000. Monashee Investment Management LLC purchased a new position in shares of Spyglass Pharma during the 1st quarter worth approximately $2,461,000. Finally, Affinity Asset Advisors LLC purchased a new stake in Spyglass Pharma in the 1st quarter valued at approximately $6,478,000.
Spyglass Pharma Company Profile
(
Get Free Report)
SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients' regular use of eye drops. The company's lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma's work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Spyglass Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list.
While Spyglass Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.